Are cancer patients in remission at higher risk of severe COVID-19? – Oncology Central
Researchers have suggested that patients in remission also face a significantly higher risk of severe COVID-19
Related Articles
Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol | Future Oncology
OPTYX is a multi-center, prospective, observational study designed to further understand the actual experience of patients with advanced prostate cancer treated with relugolix (ORGOVYX®), an…
Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol | Future Oncology
OPTYX is a multi-center, prospective, observational study designed to further understand the actual experience of patients with advanced prostate cancer treated with relugolix (ORGOVYX®), an…
A journey through value-based oncology care
What challenges are associated with value-based oncology care and how can these be overcome?
Frontiers in brain tumor research and empowering women in STEM
Discover the strides being made to unravel the complexities of brain tumors in our latest interview with Karen Noble.
A journey through value-based oncology care
What challenges are associated with value-based oncology care and how can these be overcome?
Championing diversity and inclusion in neuro-oncology
Explore opportunities for women in neuro-oncology with Dr Macarena Ines De La Fuente who has been the co-chair of the SNO’s Women and Diversity Committee.
How can AI help provide real-time insights into glioblastoma disease progression?
How can MRI-guided radiation therapy offer in terms of real-time insights into glioblastoma disease progression?
A journey through value-based oncology care
What challenges are associated with value-based oncology care and how can these be overcome?
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions | Future Oncology
Neuregulin 1 (NRG1) fusions are oncogenic drivers that have been detected in non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. NRG1…
The Phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
eNRGy is a clinical trial of zenocutuzumab for cancer caused by NRG1 gene fusions. Find out more in our latest journal feature here.